Literature DB >> 31392147

Changes in testosterone prescribing patterns after FDA warning.

Soum D Lokeshwar1, Joshua Bitran1, Ranjith Ramasamy1.   

Abstract

Entities:  

Year:  2019        PMID： 31392147      PMCID： PMC6642974          DOI： 10.21037/tau.2019.04.03

Source DB:  PubMed          Journal:  Transl Androl Urol        ISSN： 2223-4683


× No keyword cloud information.
  5 in total

1.  Re: Testosterone Products: Drug Safety Communication - FDA Cautions about Using Testosterone Products for Low Testosterone due to Aging; Requires Labeling Change to Inform of Possible Increased Risk of Heart Attack and Stroke.

Authors:  Allen D Seftel
Journal:  J Urol       Date:  2015-06-18       Impact factor: 7.450

2.  Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels.

Authors:  Rebecca Vigen; Colin I O'Donnell; Anna E Barón; Gary K Grunwald; Thomas M Maddox; Steven M Bradley; Al Barqawi; Glenn Woning; Margaret E Wierman; Mary E Plomondon; John S Rumsfeld; P Michael Ho
Journal:  JAMA       Date:  2013-11-06       Impact factor: 56.272

Review 3.  Testosterone, aging and survival: biomarker or deficiency.

Authors:  Molly M Shores; Alvin M Matsumoto
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2014-06       Impact factor: 3.243

4.  Trends in androgen prescribing in the United States, 2001 to 2011.

Authors:  Jacques Baillargeon; Randall J Urban; Kenneth J Ottenbacher; Karen S Pierson; James S Goodwin
Journal:  JAMA Intern Med       Date:  2013-08-12       Impact factor: 21.873

5.  Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men.

Authors:  William D Finkle; Sander Greenland; Gregory K Ridgeway; John L Adams; Melissa A Frasco; Michael B Cook; Joseph F Fraumeni; Robert N Hoover
Journal:  PLoS One       Date:  2014-01-29       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.